Association for Accessible Medicines

Joanne Duncan joins AAM as chief operating officer

Joanne Duncan joins AAM as chief operating officer

WASHINGTON  — Today Joanne Duncan is joining the Association for Accessible Medicines as chief operating officer. She will be responsible for leading and managing implementation of a more comprehensive member recruitment strategy. She will drive operational improvement by increasing the alignment between issue prioritization and the budgeting process, maximizing IT functionality and human resources capabilities.

Video Forum: Dan Leonard, Association for Accessible Medicines

Video Forum: Dan Leonard, Association for Accessible Medicines

  Dan Leonard, longtime leader of the National Pharmaceutical Council who became CEO of the Association for Accessible Medicines in September, discusses the impact of generic medications on health care, and the challenges and opportunities facing the industry. Among the issues addressed are generics’ role in treating COVID-19 patients, the emergence of biosimilars, and the

AAM issues statement on 2020 election

AAM issues statement on 2020 election

WASHINGTON — The Association for Accessible Medicines’ president and CEO Dan Leonard issued the following statement on the 2020 election: “The Association for Accessible Medicines looks forward to working with the incoming Biden-Harris administration to achieve our shared goal of increasing access to safe, effective and affordable generic and biosimilar prescription medicines for all Americans.

Making the Rx markets more competitive again

Making the Rx markets more competitive again

Editor’s note: This was part of CDR’s 2019 Pharmacy Outlook in the January 7 issue. This past June, Secretary of Health and Human Services Alex Azar told the Senate Finance Committee, “We need a strong, robust generic market.” He followed this statement with an observation that resonated for many of the member companies of the

Generic drugs see low abandonment rate

Generic drugs see low abandonment rate

WASHINGTON — Prescription abandonment is sharply higher for branded drugs than generic drugs, a new annual report commissioned by the Association for Accessible Medicines (AAM) found. AAM said Monday that abandonment — defined as the failure to pick up a new script — was nearly three times as high for brand-name drugs as for generics

AAM: REMS abuse trips up new generics

AAM: REMS abuse trips up new generics

The Association for Accessible Medicines (AAM) said a new report shows that abuse of the Food and Drug Administration’s Risk Evaluation Mitigation Strategies (REMS) safety program is hampering the market entry of new generic drugs. This week, AAM said a report by Alex Brill, CEO of economic policy consultancy Matrix Global Advisors, titled “REMS and

New name for Generic Pharmaceutical Association

New name for Generic Pharmaceutical Association

WASHINGTON — The Generic Pharmaceutical Association (GPhA), which represents manufacturers of generic drugs and biosimilars, has changed its name to the Association for Accessible Medicines (AAM). The association said Tuesday that the new name better reflects its mission: to make medications more accessible to the people who need them. As GPhA, the trade group had steadfastly